Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Focal Segmental Glomerulosclerosis”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Testing effectiveness (Phase 2)Looking for participantsNCT06466135
What this trial is testing

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Who this might be right for
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences 96
Not applicableLooking for participantsNCT02235857
What this trial is testing

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing

Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84
Testing effectiveness (Phase 2)WithdrawnNCT00550342
What this trial is testing

Rituximab Treatment of Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis (FSGS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Testing effectiveness (Phase 2)Study completedNCT03649152
What this trial is testing

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

Who this might be right for
Focal Segmental Glomerulosclerosis
Dimerix Bioscience Pty Ltd 8
Testing effectiveness (Phase 2)Study completedNCT03422510
What this trial is testing

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Complexa, Inc. 33
Not applicableNot Yet RecruitingNCT06315504
What this trial is testing

Circulating Factors in Nephrotic Syndrome

Who this might be right for
Nephrotic SyndromeMembranous NephropathyMinimal Change Disease+1 more
Iain Bressendorff 104
Testing effectiveness (Phase 2)Ended earlyNCT03703908
What this trial is testing

CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Who this might be right for
Focal Segmental Glomerulosclerosis
Amgen 5
Early research (Phase 1)Ended earlyNCT00816478
What this trial is testing

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Who this might be right for
Focal Segmental Glomerulosclerosis
Northwell Health 15
Not applicableLooking for participantsNCT04065438
What this trial is testing

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Testing effectiveness (Phase 2)Study completedNCT04983888
What this trial is testing

Obinutuzumab in Primary FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 20
Large-scale testing (Phase 3)Study completedNCT03493685
What this trial is testing

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 371
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000
Testing effectiveness (Phase 2)Looking for participantsNCT06664814
What this trial is testing

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI) 30
Not applicableStudy completedNCT03126201
What this trial is testing

Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis

Who this might be right for
GlomerulonephritisFocal Segmental Glomerulosclerosis
Istanbul University 86
Early research (Phase 1)Study completedNCT00464321
What this trial is testing

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Who this might be right for
Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 16
Not applicableStudy completedNCT04369183
What this trial is testing

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change Disease
Istanbul University 25
Not applicableWithdrawnNCT00302536
What this trial is testing

Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Glomerulosclerosis
Nanjing University School of Medicine
Post-approval studies (Phase 4)Study completedNCT02633046
What this trial is testing

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Who this might be right for
Idiopathic Focal Segmental Glomerulosclerosis
Mallinckrodt ARD LLC 63
Post-approval studies (Phase 4)Study completedNCT01155141
What this trial is testing

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Who this might be right for
Kidney Diseases
Stanford University 15
Load More Results